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Abstract
Background: In patients hospitalized in intensive care units (ICU), Candida infections are associated with increased
morbidity, mortality and costs. However, previous studies reported confused risk factors for catheter-related Candida
bloodstream infection (CRCBSI). The objective was to describe the risk factors, microbiology, management and
outcomes of CRCBSI in the China-SCAN population.
Methods: Patients with ≥1 Candida-positive peripheral blood culture were selected from the China-SCAN study.
Peripheral and catheter blood samples were collected for Candida isolation. Patients with the same strain of
Candida in peripheral and catheter blood samples were considered as being with CRCBSI, while patients with
Candida-positive peripheral blood cultures only or different strains were considered as non-CRCBSI. Data were
collected from the China-SCAN study.
Results: CRCBSI incidence in ICU was 0.03% (29/96,060), accounting for 9.86% of all candidemia observed in ICU
(29/294). The proportion of CRCBSI due to Candida parapsilosis reached 33.3%, more than that of Candida albicans
(28.6%). In univariate analyses, older age (P = 0.028) and lower body weight (P = 0.037) were associated with CRCBSI.
Multivariate analysis showed that the sequential organ failure assessment (SOFA) score was independently
associated with CRCBSI (odds ratio (OR) = 1.142, 95% confidence interval = 1.049-1.244, P = 0.002). Catheter removal
and immune enhancement therapy were often used for CRCBSI treatment.
Conclusions: In China, CRCBSI was more likely to occur in old patients with low body weight. SOFA score was
independently associated with CRCBSI. Candida parapsilosis accounted for a high proportion of CRCBSI, but the
difference from non-CRCBSI was not significant.
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Background
Candida sp. represent the third most common family of
pathogens causing bloodstream infections in intensive
care units (ICU) patients in the United States [1-3]. The
global incidence of candidemia is reported to be 6.7-54 per
1000 ICU patients [4-6]. Untreated candidemia typically
results in eye lesions, skin lesions and abscesses, and
often lead to multiple organ failure. The mortality rate is
30–61.8% in Europe and America [5-8]. In addition,
candidemia can extend hospital stay by 10–30 days, and
increase inpatient hospital costs by about $40,000 in the
United States [8]. Candidemia requires treatment with an
antifungal agent, and removal of the catheter alone is
not an adequate therapy for candidemia [9]. The large
prospective China Survey of Candidiasis (China-SCAN)
study showed that most candidemia in China were caused
by non-albicans species (58.2%), and that first-line
antifungal therapy decreased mortality [10].
Catheters are commonly used in ICU patients, and
represent an easy entry route for pathogens, including
Candida sp. In general, patients with candidemia are inserted
with catheters, most commonly central venous catheter
(CVC), with a placement rate of 80-89% in Europe and
America [11,12]. CVC placement can significantly increase
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the risk of candidemia in hospitalized patients [13],
and is an independent risk factor for candidemia in
the United States [14]. Candidemia caused by catheter
placement is named Candida catheter-related bloodstream
infection (CRCBSI). In addition to CVC, studies in Europe
and America identified a number of risk factors that are
associated with CRCBSI such as surgical trauma, cancer,
parenteral nutrition, diabetes mellitus, urinary catheter,
age, vancomycin use, and impaired acute physiology and
chronic health evaluation (APACHE) score [8,15-19].
The epidemiology of candidemia varies with geography,
but is mostly dominated by Candida albicans; however,
the proportion of non-albicans candidemia is increasing
each year [20], sometimes reaching higher rates than that
of albicans candidemia in European countries [21]. In
many countries, Candida parapsilosis contributes to
15-20% of candidemia, and is often associated with
CRCBSI [22,23]. Therefore, a better understanding of the
CRCBSI epidemiology could lead to better first-line
treatments, and to decreased morbidity and mortality.
The China-SCAN study assessed the epidemiology,
microbiology, management and outcomes of invasive
candidiasis in 67 ICUs across China, and the results
were published [10]. The aim of the present study was
to assess the risk factors, microbiology, management and
outcomes of CRCBSI in the China-SCAN sample. Results
might lead to a better identification of patients at high risk
of CRCBSI, and to adopt appropriate clinical strategies.
Methods
Study design and patients
The methods of the China-SCAN study including inclusion
and exclusion criteria were previously published [10]. The
present study focused on patients with at least one
Candida-positive peripheral blood culture rather than
those with positive Candida in histopathological specimen
or sterile body cavities fluid specimen culture. Hence,
from 306 patients recruited in the CHINA-SCAN study,
294 patients with Candida-positive peripheral blood
cultures (290 cases with Candida-positive peripheral blood
culture only, and 4 cases with Candida-positive peripheral
blood and sterile body cavities fluid specimens) were
selected for the present study. Peripheral blood and
catheter blood were sampled simultaneously to isolate the
Candida strains; the same isolated Candida strain denoted
CRCBSI [21,24]. Patients with Candida-positive peripheral
blood culture only or with different Candida isolates were
considered as non-CRCBSI (NCRCBSI) (Figure 1).
The study was approved by the Ethics Committee
of Zhongda Hospital of Southeast University, the lead
investigation site. Other participating hospitals accepted
the central ethics committee review or conducted a
further, independent, ethics review, according to their own
institutional policy (20 hospitals). The study complied
with the Declaration of Helsinki regarding ethical principles
of human subjects research and the relevant ethical require-
ments of the International Conference on Harmonisation/
Good Clinical Practice guidance and national regulations.
All patients provided written informed consent. The
China-SCAN study is registered with ClinicalTrials.
gov (NCTT01253954).
Sample management and strain identification
All participating centers used the same transportation
method. Personnel from each center were trained
together to standardize our procedures. Peripheral and
catheter blood samples were sampled using strict aseptic
methods, and then each sample collected in aerobic and
anaerobic blood culture vials (10 ml each). Interval
between peripheral and catheter blood sampling was no
more than 5 minutes. Blood samples were immediately
sent to the sub-center’s laboratory for preliminary
screening. After preliminary screening, strains were
grown in SDA or PDA plastic tubes at 28-30°C and
cultured for 2–3 days. After growth, strains were stored at
room temperature. Within 1–2 months, strains were
transported to the central laboratory. Clinical research
assistants at each sub-center were responsible for the
regular collection of strains. Strains were shipped to the
central laboratory (Research Center for Medical Mycology,
Peking University First Hospital, Beijing, China) overnight,
at room temperature, by professional courier companies
in leak-proof, sealed, unbreakable containers. At the
central laboratory, the exact strain and its drug sens-
ibility were determined, as previously described for
the China-SCAN study [10,25].
Strains were identified as previously described for the
China-SCAN study [10,25]. Briefly, species were identified
using chromogenic culture media (CHROMagar, Paris,
France) and the API 20C AUX yeast identification kit
(bioMérieux SA, Marcy l’Étoile, France). When necessary,
large-subunit (26S) ribosomal rRNA gene D1/D2 domain
sequencing was performed. Candida haemulonii, Candida
pelliculosa, Candida ernobii, Candida norvegensis, Candida
metapsilosis and Lodderomyces elongisporus were identified
by sequencing.
Figure 1 Flow chart of patients.
Hu et al. BMC Infectious Diseases 2014, 14:594 Page 2 of 9
http://www.biomedcentral.com/1471-2334/14/594
Data collection and management
All data were from the databases of the China-SCAN
study. The content and management of the database had
been reported in details [10]. Data were collected from
case report forms, and analyzed for comparison between
CRCBSI and NCRCBSI.
The APACHE II was evaluated within 24 h of ICU
admission. An integrated score from 0 to 71 was calculated.
Higher scores indicate more severe disease and higher risk
of death [26].
The SOFA score is an ICU scoring system based on
organ function or failure rate. The score is based on scores
for the respiratory, cardiovascular, hepatic, coagulation, renal
and neurological systems [27]. This score was calculated
within 24 h of ICU admission.
Chronic hepatic insufficiency was defined as in
APACHE II: 1) biopsy-proven cirrhosis and documented
portal hypertension; 2) history of upper gastrointestinal
bleeding attributed to portal hypertension; or 3) history of
hepatic failure/encephalopathy/coma.
Statistical analysis
Statistical analysis was conducted using SAS 9.1 (SAS
Institute, Cary, NC, USA). Continuous variables are
presented as means ± standard deviation (SD) (normally dis-
tributed), or median (Q1, Q3) (non-normally distributed).
Categorical variables are presented as frequencies and
percentiles. Independent samples t-tests and Wilcoxon
rank sum tests were used for continuous variables, as
appropriate. Chi-square tests and Fisher's tests were
used for categorical data, as appropriate. Variables
with P-values <0.20 in univariate analyses were entered
into a multivariate logistic regression analysis to iden-
tify factors that were independently associated with
CRCBSI. P-values <0.05 were considered to be statistically
significant.
Results and discussion
Incidence and patient characteristics
Among the 294 identified patients, there were 265 cases
of NCRCBSI and 29 cases of CRCBSI. Patients with
CRCBSI represented 9.86% of all candidemia patients.
Based on the 96,060 ICU patients in the CHINA-SCAN
study [10], CRCBSI incidence was 0.03% of ICU patients
(29/96,060) (Figure 1).
The baseline characteristics of patients are com-
pared in Table 1. Results from univariate analyses suggest
that CRCBSI was associated with age (69.4 ± 19.1 vs.
60.7 ± 20.2 years, P = 0.028) and with body weight
(58.0 ± 5.2 vs. 63.2 ± 11.0 kg, P = 0.037). SOFA score at
candidemia diagnosis (P = 0.15), solid tumors (P = 0.18)
and chronic hepatic insufficiency (P = 0.06) were also
included in the multivariate analysis.
Catheter indwelling between the CRCBSI and NCRCBSI
groups
Among CRCBSI patients, 26 were inserted with CVC, and
the remaining three had peripheral arterial catheters.
Among the NCRCBSI patients, 217 were inserted
with CVC. There was no difference in the rate of
CVC indwelling between CRCBSI and NCRCBSI patients
(P = 0.438). CVC puncture was placed in the jugular, sub-
clavian, or femoral vein, without difference between the
groups (all P > 0.05). Indwelling time of the last catheter
before candidemia diagnosis was not different between
the groups (all P > 0.05) (Table 2).
Catheter removal between the CRCBSI and NCRCBSI
groups
There was no difference between the two groups in the
number of CVC removal from each position within two
weeks before candidemia diagnosis (all P > 0.05). Signifi-
cantly more catheters were removed in the CRCBSI group
after diagnosis (82.8 vs. 60.0%, P = 0.016) (Table 2).
Microbiology
Because of the individual hospital policy and suboptimal
storage or handling of isolates, not all isolates from other
hospitals were sent to the central laboratory for review
and identification, and a total of 237 isolates (21 from
CRCBSI patients, and 216 from NCRCBSI patients)
were identified in the central laboratory (Table 3).
The proportion of Candida parapsilosis (33.3%) was
higher than that of Candida albicans (28.6%) in the
CRCBSI group, while the proportion of Candida albicans
(40.3%) was the highest in the NCRCBSI group. However,
there was no difference in the distribution of Candida
strains between the two groups (P = 0.352). The results
derived from the different hospitals were consistent with
those obtained in the central laboratory. Additional file 1:
Table S1 presents the strains distribution across study
centers in China.
Multivariate analysis
Multivariate analysis showed that the SOFA score at candi-
demia diagnosis was independently associated with CRCBSI
(odds ratio = 1.142, 95% confidence interval = 1.049-1.244,
P = 0.002). Solid tumors (P = 0.08), chronic hepatic insuffi-
ciency (P = 0.82), age (P = 0.16) and body weight (P = 0.58)
were not associated with CRCBSI (Table 4).
Antifungal treatment
Twenty-eight CRCBSI patients (28/29, 96.6%) received
antifungal treatment, without difference from the NCRCBSI
group (229/265, 86.4%; P > 0.05) (Table 1). The more
frequently used drugs were fluconazole, followed by caspo-
fungin and voriconazole. The course of antifungal therapy
was similar between the two groups. More CRCBSI patients
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Table 1 Baseline characteristics of 294 patients with Candida bloodstream infection in the CHINA-SCAN study,
according to CRCBSI and NCRCBSI
Variables CRCBSI NCRCBSI P-value
N = 29 N = 265
Age (years), mean ± SD 69.4 ± 19.1 60.7 ± 20.2 0.028*
Gender, n (%) 0.527
Male 22 (75.9) 181 (68.3)
Female 7 (24.1) 84 (31.7)
Body weight (kg), mean ± SD 58.0 ± 5.2 63.2 ± 11.0 0.037*
Symptoms, n (%)
Fever 27 (93.1) 243 (91.7) 1.000
Shivers 8 (27.6) 83 (31.3) 0.833
Confusion 13 (44.8) 123 (46.4) 1.000
Concomitant disease, n (%)
Type 1 or 2 diabetes 7 (24.1) 59 (22.3) 0.833
Chronic cardiac dysfunction 6 (20.7) 57 (21.5) 0.891
Solid tumor 8 (27.6) 45 (16.9) 0.180
Chronic obstructive pulmonary disease 4 (13.8) 31 (11.7) 0.762
Chronic renal insufficiency 5 (17.2) 27 (10.2) 0.259
Chronic hepatic insufficiency 4 (13.8) 12 (4.5) 0.060
Hematological malignancy 0 (0.0) 3 (1.2) 1.000
Invasive procedures within 2 weeks prior to diagnosis, n (%)
Hemodialysis 2 (6.9) 15 (5.7) 0.259
Invasive mechanical ventilation 24 (82.7) 204 (77.0) 0.666
Total parenteral nutrition 14 (48.3) 115 (43.4) 0.695
Surgery 11 (37.9) 102 (38.5) 1.000
Immunosuppression 2 (6.9) 15 (5.7) 0.679
Illness severity at ICU admission, mean ± SD
APACHE II score 28.5 ± 7.6 27.0 ± 7.1 0.286
SOFA score 10.6 ± 2.9 11.2 ± 3.5 0.330
Illness severity at diagnosis, mean ± SD
APACHE II score 28.2 ± 7.2 27.0 ± 7.0 0.360
SOFA score 9.8 ± 3.3 10.8 ± 3.5 0.147
Immune enhancement therapy, n (%)a 21 (72.4) 102 (38.5) <0.001**
Antibiotic use, n (%) 0.963
Monotherapy 8 (32.0) 75 (35.9)
Two-drug combinations 13 (52.0) 98 (46.9)
Three-drug combinations 4 (16.0) 35 (16.7)
Antibiotic use period, mean ± SD 11.4 ± 4.2 10.6 ± 6.5 0.514
Antibiotic therapy >5 days, n (%) 25 (86.2) 209 (78.9) 0.469
Antifungal therapy, n (%) 28 (96.6%) 229 (86.4%) 0.118
Initial antifungal treatment, n (%) 0.977
Fluconazole 11 (39.3%) 84 (36.7%)
Caspofungin 7 (25.0%) 54 (23.6%)
Voriconazole 4 (14.3%) 44 (19.2%)
Micafungin 3 (10.7%) 20 (8.7%)
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received immune enhancement therapy (immunoglobulins
and/or thymosin α1) (72.4% vs. 38.5%; P < 0.001) (Table 1).
However, because it only was an observational indicator,
the types and doses of immunoglobulins and thymosin α1
were not recorded.
Treatment outcomes
CRCBSI patients showed a non-significant higher mortality
(44.8% vs. 36.2%; P = 0.419). Trends toward longer ICU
stay (median: 34 vs. 25 days; P = 0.095) and hospitalization
(median: 54 vs. 39 days; P = 0.096) were also observed.
CRCBSI patients were more likely to experience microbio-
logical recovery compared with NCRCBSI patients (67.9%
vs. 50.0%; P < 0.001) (Table 5).
Discussion
To our knowledge, the China-SCAN study is the largest
prospective study of invasive candidiasis in Chinese
ICUs, and possibly from anywhere. In addition, it is also
one of the first to describe Candida catheter-related
bloodstream infections in China. The present study aimed
to determine the risk factors for catheter-related candide-
mia in Chinese ICU. Our results showed that CRCBSI
incidence in ICU was 0.03%, accounting for 9.86% of all
candidemia observed in ICU (29/294), mainly caused
by Candida parapsilosis in CRCBSI patients (33.3%).
Univariate analyses showed that older age and lower
body weight were associated with CRCBSI. Multivariate
analysis showed that the SOFA score was independently
associated with CRCBSI (P = 0.002). Catheter removal and
immune enhancement therapy were more frequently used
in CRCBSI than in NCRCBSI. Results of the present
study provide clues for a better identification of CRCBSI
patients.
Few studies reported large-scale epidemiological data
on CRCBSI. In the present study, we reported a CRCBSI
incidence in ICUs of 0.3/1000 patients, which was calcu-
lated based on the 96,060 ICU patients reported in the
China-SCAN study. In the present study, some patients
with NCRCBSI did not have blood sample in venous
catheter; therefore, some of these patients might in reality
be CRCBSI cases. In addition, some Candida-positive
patients could have been excluded because of the strict
inclusion criteria of the CHINA-SCAN study. Therefore,
the real CRCBSI incidence may be higher.
In the present study, the mortality rate from CRCBSI
was 44.8%, which was not significantly different from
that of NCRCBSI (36.2%). These rates are in agreement
with the published global mortality rates of 30–61.8%
in hospital-based candidemia studies from western
countries [5-8].
The CRCBSI and NCRCBSI groups were compared in
order to identify risk factors for CRCBSI. Results
showed that the two groups were similar in disease,
invasive procedures, disease severity score, and the
use of antibiotics within the past two weeks. However,
in univariate analyses, there were significant differences in
age and body weight. These results suggest that risk
factors for CRCBSI, other candidemias and invasive
candidiasis were similar in most ICU patients, except
for those with an older age and lower body weight.
CVC is the most common type of catheter causing
CRCBSI [28]. Studies have shown that CVC placement
rate in candidemia patients is 80–96.7% [21]. Consistent
with these results, the CVC placement rates in patients
with CRCBSI and those with NCRCBSI in the present
study were above 80% (89.7% and 81.9%), and there was
no significant different between the two groups. The
CVC placement position and indwelling period were
similar in both groups, indicating that the initial placement
position of catheter and catheter indwelling time were not
the cause of CRCBSI. The catheter removal rate was not
different within 2 weeks before diagnosis between the two
groups, but was significantly higher after diagnosis in the
CRCBSI group (82.8%) compared with the NCRCBSI group
(60.0%), in compliance with previous studies and guidelines
[18,29,30]. A recent study suggested that any delay in
catheter removal and initiation of antifungal therapy was
associated with increased mortality in CRCBSI patients;
however, catheter removal had no impact on mortality of
Table 1 Baseline characteristics of 294 patients with Candida bloodstream infection in the CHINA-SCAN study,
according to CRCBSI and NCRCBSI (Continued)
Itraconazole 3 (10.7%) 18 (7.9%)
Amphotericin B (liposomes or lipid dispersions) 0 5 (2.2%)
Two-drugs combinationb 0 4 (1.7%)
Treatment duration, mean ± SD 19.0 ± 13.3 16.7 ± 13.3 0.338
Antifungal therapy >5 days, n (%) 8 (27.6) 70 (26.4) 1.000
Time between ICU admission and diagnosis of Candida infection (days), median (Q1,Q3) 11.0 (4.0, 26.0) 10.00 (4.0, 21.0) 0.544
*P<0.05, **P<0.01.
aUse of immunoglobulins and/or thymosin α1.
bFluconazole + caspofungin: 2 patients; itraconazole + fluconazole: 1 patient; amphotericin B + caspofungin: 1 patient.
CRCBSI: catheter-related Candida bloodstream infection; NCRCBSI: non-catheter-related Candida bloodstream infections; ICU: intensive care unit; APACHE: acute
physiology and chronic health evaluation II; SOFA: sequential organ failure assessment.
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NCRCBSI patients [18]. On the other hand, some studies
argued that CVC removal do not affect prognosis of
candidemia [31]. The 2012 ESCMID guidelines also pointed
out that catheter removal is necessary for candidemia,
but that antifungal treatment can be used if catheter
removal is impossible [32].
In the present study, multivariate analysis showed
that the SOFA score was the only independent variable
associated with CRCBSI. We explored a number of factors
that have been shown to be associated with candidemia in
previous studies, but we did not observe any association
between these parameters and CRCBSI. The study by
MacDonald et al. [19] showed that hyperalimentation was
the only independent risk factor for candidemia in an ICU
pediatric population. Another pediatric study showed that
CVC, cancer, recent use of vancomycin, and use of agents
against anaerobic bacteria were independent factors
associated with candidemia [8]. A study showed that
independent predictors of biofilm-forming candidemia
were the use of CVC, the use of urinary catheters,
parenteral alimentation, and diabetes [15]. Finally, a study
showed that an inadequate antifungal therapy, infection
with biofilm-forming Candida species, and APACHE III
scores were associated with higher Candida-related
mortality [16]. However, these studies did not differentiate
between CRCBSI and NCRCBSI. In addition, the only risk
factor for candidemia that was common to these studies
was the use of CVC.
Because there is variability in the resistance of Candida
strains to storage and transport, some samples could not be
tested in the central laboratory, and the exact distribution
of the different Candida species might have suffered from
this bias. However, we observed that CRCBSI was mainly
associated with Candida parapsilosis, while NCRCBSI was
mainly associated with Candida albicans, although the
Table 3 Candida strains according to CRCBSI and NCRCBSI
Strain CRCBSI NCRCBSI P-value
N = 21 N = 216
Candida strains isolates, n (%) 0.352
Candida albicans 6 (28.6) 87 (40.3)
Candida parapsilosis 7 (33.3) 48 (22.2)
Candida tropicalis 2 (9.5) 37 (17.1)
Candida glabrata 2 (9.5) 25 (11.6)
Others 4 (19.0) 19 (8.7)
Table 2 Indwelling and removal of catheters according to CRCBSI and NCRCBSI
Category CRCBSI NCRCBSI P-value
N = 29 N = 265
Indwelling central venous catheter, n (%)a 0.438
Yes 26 (89.7) 217 (81.9)
No 3 (10.3) 48 (18.1)
Catheter indwelling position, n (%)
Jugular vein 12 (41.4) 107 (40.4) 1.000
Subclavian vein 13 (44.8) 104 (39.2) 0.556
Femoral vein 8 (27.6) 75 (28.3) 1.000
Catheter removal from each position, n (%)b
Jugular vein A 2 (6.9) 19 (7.2) 0.335
B 0 (0) 22 (8.3)
Subclavian vein A 5 (17.2) 17 (6.4) 0.251
B 2 (6.9) 29 (10.9)
Femoral vein A 2 (6.9) 14 (5.3) 0.960
B 2 (6.9) 20 (7.5)
Period of catheter indwelling in the last time (days), median (min, max)
Jugular vein 10.00 (4.0, 13.0) 8.00 (−1.0, 382.0) 0.827
Subclavian vein 14.00 (1.0, 30.0) 9.00 (−337.0, 63.0) 0.150
Femoral vein 5.00 (1.0, 18.0) 9.00 (−58.0, 369.0) 0.161
Catheter removal after diagnosis, n (%) 24 (82.8) 159 (60.0) 0.016*
* P < 0.05.
aIncludes patients who were catheterized within 2 weeks of the first positive sample but in whom the catheter was removed before diagnosis.
bAnalysis of catheter removal within 2 weeks before diagnosis. A: catheter was removed at some time in the 2-week period before diagnosis, but a catheter was
in place at diagnosis. B: catheter was removed in the 2-week period before diagnosis, and there was no catheter in place at diagnosis.
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distribution of strains between the two groups was
not different. This observation was consistent with
previous studies on candidemia [6,25,33]. Candida
parapsilosis is more prone to cause CRCBSI, which
may be related to its ease of growing in intravenous
infusion of high-sugar-based nutrition, to its growing
in CVC biofilm that can easily be spread by the hands of
medical personnel, and to its long-term survival [33].
Using catheter removal and appropriate antifungal
therapy, CRCBSI microbiological clearance rate was
significantly higher than that of NCRCBSI (67.9% vs.
50.0%), which was consistent with a previous study [18].
There was no difference in antifungal treatment between
CRCBSI and NCRCBSI patients in respect to antifungal
treatment. The most commonly used was fluconazole,
followed by caspofungin and voriconazole. In the
China-SCAN flora and sensitivity analysis, patients
with non-albicans strains were more susceptible to
require a therapy adjustment [10]. Considering the high
proportion of Candida parapsilosis causing CRCBSI in
the present study, we suggest to consider drugs with
a higher efficacy against Candida parapsilosis in the
treatment of CRCBSI.
Although there is no clear indicator of the presence
of immunosuppression in the present study, ICU physi-
cians rely on clinical experience to use immunotherapy.
More CRCBSI patients received immune enhancement
therapy (72.4% vs. 38.5%), suggesting that ICU physi-
cians are concerned about CRCBSI-related immune
suppression. From the previously identified risk factors
in patients with CRCBSI [8,15-19], patients with old
age and low body weight might be more prone to
develop immunosuppression. Although no immune en-
hancement therapy is clearly recognized to improve
CRCBSI patients’ prognosis, immunoglobulins and thy-
mosin α1 were selected as immunotherapy since these
drugs have a potential to improve prognosis in sepsis
patients [34,35].
The China-SCAN study suffered from some limita-
tions that also have an impact in the present study.
Indeed, the lack of central validation for some samples
could lead to an underestimation of the real CRCBSI
incidence, as well as for the Candida strains causing
CRCBSI. However, results based from the central labora-
tory clearly demonstrated that the proportion of Candida
parapsilosis was higher in the CRCBSI group, while that
of Candida albicans was higher in the NCRCBSI group.
Differences in therapeutic strategies across the study
centers may have contributed to biases in diagnosis,
treatments and prognosis. Concerning the present study,
the sample size of the CRCBSI group was small.
Therefore, results need to be verified in further large-scale
studies on CRCBSI.
Conclusions
In China, CRCBSI was more likely to occur in old
patients with low body weight. SOFA score was inde-
pendently associated with CRCBSI. Candida parapsilosis
accounted for a high proportion of CRCBSI, but the
difference from NCRCBSI was not significant.
Table 5 Treatment outcomes according to CRCBSI/NCRCBSI
Category CRCBSI NCRCBSI P-value
n = 29 n = 265
Mortality, n (%) 13 (44.8) 96 (36.2) 0.419
ICU stay period (days), median (Q1,Q3) 34.00 (18.0, 71.0) 25.00 (13.0, 44.0) 0.095
Hospital stays (days), median (Q1,Q3) 54.00 (26.0, 91.0) 39.00 (18.0, 69.5) 0.096
Candida elimination, n (%) 19 (67.9) 116 (50.0) 0.001**
Time from positive to negative blood culture (days), median (Q1,Q3) 14.00 (6.0, 24.0) 17.00 (12.0, 26.0) 0.275
**P<0.01












Solid tumors (yes vs. other Concomitant disease) 0.344 0.1954 3.1008 1.990 0.925 4.279 0.0783
Chronic hepatic insufficiency (yes vs. other
concomitant disease)
−0.1596 0.7118 0.0503 0.852 0.211 3.44 0.8226
Age 0.0112 0.00808 1.9336 1.011 0.995 1.027 0.1644
SOFA score at diagnosis 0.1329 0.0436 9.2834 1.142 1.049 1.244 0.0023**
Body weight −0.00817 0.0149 0.3021 0.992 0.963 1.021 0.5825
**P<0.01
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Additional file
Additional file 1: Table S1. Candida strains by center.
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